

[FORM 44]

(See rules 122A, 122B, 122D and 122 DA)

Application for grant of permission to import or manufacture a New Drug or to undertake clinical trial.

I/We*..... of M/s..... (address) hereby apply for grant of permission for import of and/or clinical trial or for approval to manufacture a new drug or fixed dose combination or subsequent permission for already approved new drug. The necessary information / data is given below :

1. Particulars of new drug :

- (1) Name of the drug.
- (2) Dosage form.
- (3) Composition of the formulation :
- (4) Test specification. (i) active ingredients. (ii) inactive ingredients.
- (5) Pharmacological classification of the drug.
- (6) Indications for which proposed to be used.
- (7) Manufacturer of the raw material (bulk drug substances).
- (8) Patent status of the drug.

2. Data submitted along with the application (as per Schedule Y with indexing and page numbers:)

A. Permission to market a new drug :

- (1) Chemical and Pharmaceutical information.
- (2) Animal Pharmacology.
- (3) Animal Toxicology.
- (4) Human / Clinical Pharmacology (Phase I).
- (5) Exploratory Clinical Trials (Phase II).
- (6) Confirmatory Clinical Trials (Phase III) (including published review articles)
- (7) Bio-availability, dissolution and stability study data.
- (8) Regulatory status in other countries.
- (9) Marketing information :
 - (a) Proposed product monograph.
 - (b) Drafts of labels and cartons.
- (10) Application for test licence.

B. Subsequent approval / permission for manufacture of already approved new drug :

(a) Formulation:

- (1) Bio-availability / bio-equivalence protocol.
- (2) Name of the investigator/center.
- (3) Source of raw material (bulk drug substances) and stability study data.

(b) Raw material (bulk drug substances):

- (1) Manufacturing method.
- (2) Quality control parameters and/or analytical specification, stability report.
- (3) Animal toxicity data.

C. Approval / Permission for fixed dose combination:

- (1) Therapeutic Justification.
(authentic literature in pre-reviewed journals/text books)
- (2) Data on pharmacokinetics/pharmacodynamics combination.
- (3) Any other data generated by the applicant on the safety and efficacy of the combination.

D. Subsequent Approval or approval for new indication - new dosage form:

- (1) Number and date of Approval / permission already granted.
- (2) Therapeutic justification for new claim / modified dosage form
- (3) Data generated on safety, efficacy and quality parameters.

A total fee of rupees.....(in words)..... has been credited to the Government under the Head of Account.....(Photocopy of receipt is enclosed).

Dated :.....

Signature.....

Designation.....

Note: *Delete whichever is not applicable.